Evolutionary Double-Bind Therapy Overcomes Prostate Cancer Resistance

Researchers discover a strategy to combat cancer's ability to evolve resistance to treatments.

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

A recent study has revealed a potentially groundbreaking strategy to combat cancer's ability to evolve resistance to treatments. Researchers have discovered an 'evolutionary double-bind' where adaptation to one therapy inadvertently makes cancer cells more vulnerable to another. The study focused on how cancer cells develop resistance to radiation therapy, finding that the adaptations that help them survive radiation also make them more susceptible to natural killer (NK) cell-mediated killing. When radiation therapy was followed by NK cell-based immunotherapy, the combination proved more effective than either treatment alone, suppressing both sensitive and resistant cancer cell populations.

Why it matters

Many patients with metastatic cancers initially respond well to treatment, but cancer cells possess a remarkable ability to evolve resistance to even the most effective therapies. This resistance allows the cancer to recur, leading to treatment failure and patient death. This new strategy offers a potential way to combat this evolutionary process and design more effective cancer treatments.

The details

The research found that cancer cells become resistant to radiation and other DNA-damaging treatments by increasing their expression of DNA repair pathways. However, these radiation-resistant cells also undergo predictable molecular changes, increasing their expression of specific cellular membrane proteins called ligands. These ligands are recognized by natural killer (NK) cells, a crucial component of the immune system that targets and destroys cancer cells. Essentially, the very adaptations that help cancer cells survive radiation simultaneously make them more susceptible to NK cell-mediated killing, creating the 'evolutionary double-bind.'

  • The study was published in the International Journal of Radiation Oncology*Biology*Physics in 2026.

The players

Robert Gatenby

A senior member of the research team from the Moffitt Cancer Center.

Cliona O'Farrelly

Professor of Comparative Immunology at Trinity College Dublin and a senior author of the study.

Kimberly Luddy

A researcher from the Moffitt Cancer Center who completed much of the work during her Ph.D. at Trinity.

Got photos? Submit your photos here. ›

What they’re saying

“The strategy is analogous to methods that might be used to control a rodent population in an agricultural field. You might start by introducing owls, but the rodents can adapt by hiding under bushes. Here, the addition of snakes represents an evolution double bind—rodents trying to escape the owls are vulnerable to the snake and, if they avoid the snakes by staying away from bushes, they are easy prey to the owls.”

— Robert Gatenby, Senior member of the research team (newsdirectory3.com)

“Importantly, this work challenges a long-held assumption in cancer biology that resistance must come at a fitness cost. Our work shows that even when resistant cells grow faster than sensitive ones, a double-bind strategy can still be effective if the second therapy preferentially targets the resistance itself. This is very exciting as it also provides a blueprint for how we can intentionally steer tumor evolution, rather than simply trying to react to resistance after it emerges. It moves evolutionary therapy from a conceptual idea to a testable, quantitative treatment design strategy.”

— Cliona O'Farrelly, Professor of Comparative Immunology (newsdirectory3.com)

What’s next

The researchers are committed to rapidly translating this work towards clinical application as the research progresses.

The takeaway

This study provides the first quantifiable and validated evidence of a strategy to exploit cancer's evolutionary adaptations, transforming resistance into an exploitable weakness. It offers a new avenue for designing more effective cancer treatments that can anticipate and overcome the cancer's ability to evolve resistance over time.